Panelists discuss how identifying type 2 inflammation in patients influences treatment decisions by steering clinicians toward targeted therapies, such as biologics or other immunomodulators, that ...

Panelists discuss how biomarkers of type 2 inflammation, such as blood eosinophils, serum IgE, and fractional exhaled nitric oxide, can aid in diagnosing and monitoring type 2 inflammatory diseases as ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Patients receiving mepolizumab vs. placebo had a smaller ...

Regeneron and Sanofi are confident that the additional analyses strongly support the approval of Dupixent in COPD with evidence of type 2 inflammation, and are committed to working with the FDA to ...

A GSK drug that targets a pathway behind the lung inflammation in chronic obstructive pulmonary disease, or COPD, has won a long-awaited FDA approval, positioning the biologic medicine to reach ...

Etokimab (I-Mab Biopharma), which is optimized for common IL-33 gene polymorphisms, has completed patient recruitment in its ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. At 52 weeks, patients receiving dupilumab vs. placebo ...

Obesity, inflammation, and type 2 diabetes are interconnected in a cyclical way. Obesity causes chronic inflammation, which helps drive the development and progression of type 2 diabetes. Diabetes, in ...